These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors. Chung JS; Ramani V; Kobayashi M; Fattah F; Popat V; Zhang S; Cruz PD; Gerber DE; Ariizumi K Clin Cancer Res; 2020 Mar; 26(6):1449-1459. PubMed ID: 31822499 [TBL] [Abstract][Full Text] [Related]
4. DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells. Tomihari M; Chung JS; Akiyoshi H; Cruz PD; Ariizumi K Cancer Res; 2010 Jul; 70(14):5778-87. PubMed ID: 20570888 [TBL] [Abstract][Full Text] [Related]
6. Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the Kobayashi M; Chung JS; Beg M; Arriaga Y; Verma U; Courtney K; Mansour J; Haley B; Khan S; Horiuchi Y; Ramani V; Harker D; Gopal P; Araghizadeh F; Cruz PD; Ariizumi K Clin Cancer Res; 2019 Jan; 25(2):828-838. PubMed ID: 30049749 [TBL] [Abstract][Full Text] [Related]
7. Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation. Chung JS; Dougherty I; Cruz PD; Ariizumi K J Immunol; 2007 Nov; 179(9):5778-84. PubMed ID: 17947650 [TBL] [Abstract][Full Text] [Related]
8. DC-HIL is a negative regulator of T lymphocyte activation. Chung JS; Sato K; Dougherty II; Cruz PD; Ariizumi K Blood; 2007 May; 109(10):4320-7. PubMed ID: 17284525 [TBL] [Abstract][Full Text] [Related]
9. Myeloid cells' evasion of melanoma immunity. Wang J; Chen L J Invest Dermatol; 2014 Nov; 134(11):2675-2677. PubMed ID: 25318429 [TBL] [Abstract][Full Text] [Related]
10. IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment. Mattei F; Schiavoni G; Sestili P; Spadaro F; Fragale A; Sistigu A; Lucarini V; Spada M; Sanchez M; Scala S; Battistini A; Belardelli F; Gabriele L Neoplasia; 2012 Dec; 14(12):1223-35. PubMed ID: 23308054 [TBL] [Abstract][Full Text] [Related]
11. Molecular cloning of a dendritic cell-associated transmembrane protein, DC-HIL, that promotes RGD-dependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans. Shikano S; Bonkobara M; Zukas PK; Ariizumi K J Biol Chem; 2001 Mar; 276(11):8125-34. PubMed ID: 11114299 [TBL] [Abstract][Full Text] [Related]
12. Human melanoma cells inhibit the earliest differentiation steps of human Langerhans cell precursors but failed to affect the functional maturation of epidermal Langerhans cells. Berthier-Vergnes O; Gaucherand M; Péguet-Navarro J; Plouet J; Pageaux JF; Schmitt D; Staquet MJ Br J Cancer; 2001 Dec; 85(12):1944-51. PubMed ID: 11747338 [TBL] [Abstract][Full Text] [Related]
13. The metastatic microenvironment: Brain-derived soluble factors alter the malignant phenotype of cutaneous and brain-metastasizing melanoma cells. Klein A; Sagi-Assif O; Izraely S; Meshel T; Pasmanik-Chor M; Nahmias C; Couraud PO; Erez N; Hoon DS; Witz IP Int J Cancer; 2012 Dec; 131(11):2509-18. PubMed ID: 22447293 [TBL] [Abstract][Full Text] [Related]
14. Autolymphocyte therapy. II. Dependence of in vivo anti-tumor specificity and long-term immunity against murine melanoma and carcinoma on ex vivo activated donor memory T-cells. Gold JE; Osband ME Clin Immunol Immunopathol; 1994 Jun; 71(3):325-32. PubMed ID: 7911078 [TBL] [Abstract][Full Text] [Related]
15. Depleting syndecan-4+ T lymphocytes using toxin-bearing dendritic cell-associated heparan sulfate proteoglycan-dependent integrin ligand: a new opportunity for treating activated T cell-driven disease. Akiyoshi H; Chung JS; Tomihari M; Cruz PD; Ariizumi K J Immunol; 2010 Apr; 184(7):3554-61. PubMed ID: 20176742 [TBL] [Abstract][Full Text] [Related]
16. Innate and adoptive immune cells contribute to natural resistance to systemic metastasis of B16 melanoma. Umeshappa CS; Zhu Y; Bhanumathy KK; Omabe M; Chibbar R; Xiang J Cancer Biother Radiopharm; 2015 Mar; 30(2):72-8. PubMed ID: 25714591 [TBL] [Abstract][Full Text] [Related]
17. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma. Gold JE; Zachary DT; Osband ME Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164 [TBL] [Abstract][Full Text] [Related]
18. Intravenous administration of bone marrow-derived multipotent mesenchymal stromal cells enhances the recruitment of CD11b(+) myeloid cells to the lungs and facilitates B16-F10 melanoma colonization. Souza LE; Almeida DC; Yaochite JN; Covas DT; Fontes AM Exp Cell Res; 2016 Jul; 345(2):141-9. PubMed ID: 26027946 [TBL] [Abstract][Full Text] [Related]
19. VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation. Huang H; Langenkamp E; Georganaki M; Loskog A; Fuchs PF; Dieterich LC; Kreuger J; Dimberg A FASEB J; 2015 Jan; 29(1):227-38. PubMed ID: 25361735 [TBL] [Abstract][Full Text] [Related]
20. CYP4A in tumor-associated macrophages promotes pre-metastatic niche formation and metastasis. Chen XW; Yu TJ; Zhang J; Li Y; Chen HL; Yang GF; Yu W; Liu YZ; Liu XX; Duan CF; Tang HL; Qiu M; Wang CL; Zheng H; Yue J; Guo AM; Yang J Oncogene; 2017 Aug; 36(35):5045-5057. PubMed ID: 28481877 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]